FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

The FDA selected Eli Lilly and Regeneron, among seven companies, for a pilot program aimed at accelerating reviews of new domestic pharmaceutical manufacturing facilities. The initiative could modestly benefit participating companies by shortening approval timelines for U.S. plant buildouts. The news is positive for Lilly and Regeneron, though the immediate market impact is likely limited.

Analysis

The FDA selected Eli Lilly and Regeneron, among seven companies, for a pilot program aimed at accelerating reviews of new domestic pharmaceutical manufacturing facilities. The initiative could modestly benefit participating companies by shortening approval timelines for U.S. plant buildouts. The news is positive for Lilly and Regeneron, though the immediate market impact is likely limited.